Massimiliano Dall’Ora

Evotec (United States) — United States

Medicine · Health Sciences

12h-index523citations30works8.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(7), CAR-T cell therapy research(7), Monoclonal and Polyclonal Antibodies Research(6), Sarcoma Diagnosis and Treatment(5), Cancer Research and Treatments(5)

Publications30 total

Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma
Cell Reports Medicine·2024· 9 citedOpen Access
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
npj Precision Oncology·2024· 8 citedOpen Access
Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells
Cytotherapy·2023· 6 citedOpen Access
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model
Leukemia·2023· 20 citedOpen Access
GD2 CAR T cells against human glioblastoma
npj Precision Oncology·2021· 76 citedOpen Access
Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma
Translational Oncology·2021· 17 citedOpen Access
Anti-GD2 chimeric antigen receptor & trail modified mesenchymal progenitors as novel strategy against ewing’s sarcoma
Cytotherapy·2021Open Access
5P Anti-GD2 chimeric antigen receptor & TRAIL modified mesenchymal progenitors as novel strategy against Ewing’s sarcoma
Annals of Oncology·2021Open Access
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
Scientific Reports·2021· 10 citedOpen Access
TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma.
PubMed·2021· 7 citedOpen Access
Arming Mesenchymal Stromal/Stem Cells Against Cancer: Has the Time Come?
Frontiers in Pharmacology·2020· 33 citedOpen Access
Targeting pancreatic ductal adenocarcinoma & its stroma by a chemo & gene therapy strategy
Cytotherapy·2020Open Access
Abstract A17: Challenging pancreatic ductal adenocarcinoma and its stroma by a combination of chemo and gene therapy: A preclinical study
Cancer Research·2019· 1 citedOpen Access
Abstract 216: Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts
Cancer Research·2018· 1 cited
Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function
Frontiers in Cell and Developmental Biology·2017· 38 citedOpen Access
Transcriptome analyses unveils the unique requirement for human lipoproteins for optimal ex-vivo expansion of cultured red blood cells for transfusion.
2017Open Access
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
Oncotarget·2017· 23 citedOpen Access
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
Oncotarget·2016· 46 citedOpen Access
Abstract 1200: HER-2 isoform interaction in mammary carcinoma onset and progression
Cancer Research·2016
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
Oncotarget·2015· 72 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Pier‐Luigi Lollini(14), Arianna Palladini(13), Patrizia Nanni(13), Giulia Grisendi(12), Massimo Dominici(12), Giordano Nicoletti(12), Carla De Giovanni(12), Marianna L. Ianzano(12), Lorena Landuzzi(11), Valentina Grosso(9), Giulia Golinelli(8), Carlotta Spano(8), Dario Ranieri(8), Manuela Iezzi(8), Roberta Laranga(8), Giulia Casari(8), Malvina Prapa(6), Chiara Chiavelli(6), Tania Balboni(6), Olivia Candini(5)